You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 10,875,893


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,875,893
Title:Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Abstract: In some aspects, the present invention provides compositions and methods of treatment comprising long-acting compstatin analogs. In some aspects, long-acting compstatin analogs comprise a clearance-reducing moiety attached to two compstatin analog moieties, wherein each compstatin analog moiety comprises a cyclic peptide comprising the amino acid sequence as set forth in SEQ ID NO: 28 extended by a lysine residue or a sequence comprising a lysine residue at the N-terminus, C-terminus, or both, wherein the lysine residue is separated from the cyclic portion of the peptide by a spacer comprising 8-amino-3,6-dioxaoctanoic acid (AEEAc) moiety, the clearance reducing moiety comprises a polymer, wherein each end of the polymer is linked to one of the compstatin analog moieties by way of a linker moiety that is or comprises a carbamate, and wherein the polymer is a PEG having an average molecular weight of about 40 kDa.
Inventor(s): Francois; Cedric (Prospect, KY), Deschatelets; Pascal (Prospect, KY)
Assignee: Apellis Pharmaceuticals, Inc. (Waltham, MA)
Application Number:16/020,987
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 10,875,893

Introduction

Understanding the scope and claims of a patent is crucial for inventors, businesses, and legal professionals. This article delves into the details of United States Patent 10,875,893, focusing on its claims, scope, and the broader patent landscape.

Patent Overview

United States Patent 10,875,893 is associated with Apellis Pharmaceuticals Inc., a company known for its innovative pharmaceutical products. To analyze this patent, we need to look at its core components:

Inventors and Assignees

The patent is assigned to Apellis Pharmaceuticals Inc., with inventors such as Cedric Francois and Pascal Deschatelets, who are key figures in the development of the patented technology[4].

Patent Issue Date and Expiration

The patent was issued on December 29, 2020. The expiration date, considering standard patent terms and any potential extensions, would typically be 20 years from the filing date, unless extended under specific provisions like the Hatch-Waxman Act[4].

Claims Analysis

Claim Structure

Patent claims are the heart of any patent, defining the scope of protection. For U.S. Patent 10,875,893, the claims can be categorized into independent and dependent claims.

  • Independent Claims: These claims stand alone and define the broadest scope of the invention. They are critical in determining the patent's scope and are often the subject of litigation and licensing negotiations[3].
  • Dependent Claims: These claims build upon the independent claims, adding specific limitations and details. They help in narrowing down the invention and can provide additional protection against infringement[3].

Claim Language and Scope

The language used in the claims is precise and technical, reflecting the complexity of the invention. For example, claims might describe specific chemical structures, manufacturing processes, or methods of use. The scope of these claims is measured using metrics such as independent claim length and independent claim count, which can indicate the breadth and clarity of the patent[3].

Patent Scope

Metrics for Measuring Scope

Research has shown that metrics like independent claim length and independent claim count can be effective in measuring patent scope. These metrics can correlate with other indicators such as patent maintenance payments, forward citations, and the breadth of patent classes[3].

Impact on Innovation

The scope of a patent can significantly impact innovation. Broader patents may lead to increased licensing and litigation costs, potentially discouraging further innovation. Conversely, narrower claims can facilitate a smoother examination process and higher grant probabilities[3].

Patent Landscape

Related Patents

Apellis Pharmaceuticals Inc. has a portfolio of patents related to the drug Empaveli (pegcetacoplan), including U.S. Patent 10,875,893. These patents cover various aspects such as the composition of the drug, methods of use, and manufacturing processes. Understanding the interplay between these patents is essential for navigating the intellectual property landscape[5].

Patent Term Extensions

Patents can be extended under certain conditions, such as delays in FDA approval. For instance, U.S. Patent 10,125,171 B2, related to the same drug, has been subject to a patent term extension application to extend its term from August 2, 2033, to March 4, 2035[4].

Search and Analysis Tools

USPTO Resources

The United States Patent and Trademark Office (USPTO) provides several resources for searching and analyzing patents. The Public Search Facility and the Main STIC Library offer expert assistance in searching foreign patents and other patent documentation[1].

Patent Claims Research Dataset

The USPTO's Patent Claims Research Dataset is a valuable resource for analyzing patent claims. It includes detailed information on claims from US patents granted between 1976 and 2014 and US patent applications published between 2001 and 2014. This dataset can help in understanding trends and metrics related to patent scope[2].

Legal and Regulatory Aspects

FDA Approval and Regulatory Review

The patent in question is associated with a drug that has undergone FDA approval. The regulatory review period and any subsequent transactions related to FDA determinations are crucial in understanding the patent's validity and enforcement[5].

Maintenance Fees and Extensions

Maintenance fees are essential for keeping a patent in force. For U.S. Patent 10,875,893, these fees would be due at specific intervals, and any extensions or adjustments would need to comply with USPTO regulations[4].

Industry Impact

Licensing and Litigation

The scope and claims of a patent like U.S. Patent 10,875,893 can significantly impact licensing agreements and litigation strategies. Broader claims may lead to more complex licensing negotiations, while narrower claims might reduce the risk of litigation[3].

Competitive Landscape

Understanding the patent landscape around Empaveli and similar drugs helps companies navigate the competitive environment. This includes monitoring patent expirations, new patent filings, and any changes in ownership or assignments[5].

Key Takeaways

  • Patent Claims: The claims of U.S. Patent 10,875,893 define the invention's scope and are critical for determining its protection.
  • Scope Metrics: Metrics like independent claim length and count help in measuring the patent's scope and its impact on innovation.
  • Related Patents: The patent is part of a broader portfolio related to Empaveli, requiring a comprehensive understanding of the interrelated patents.
  • Regulatory Aspects: FDA approval and regulatory review periods are vital in the patent's lifecycle.
  • Industry Impact: The patent's scope influences licensing, litigation, and the competitive landscape in the pharmaceutical industry.

FAQs

Q: What is the significance of independent claims in a patent? A: Independent claims define the broadest scope of the invention and are crucial in determining the patent's protection.

Q: How can the scope of a patent be measured? A: Metrics such as independent claim length and independent claim count are used to measure the scope of a patent.

Q: What is the role of the USPTO in patent searches and analysis? A: The USPTO provides resources like the Public Search Facility and the Main STIC Library, along with datasets like the Patent Claims Research Dataset, to aid in patent searches and analysis.

Q: How do maintenance fees impact a patent's validity? A: Maintenance fees are necessary to keep a patent in force; failure to pay these fees can result in the patent lapsing.

Q: What is the impact of patent scope on innovation and licensing? A: Broader patents can lead to increased licensing and litigation costs, potentially discouraging innovation, while narrower claims can facilitate smoother processes and higher grant probabilities.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. USPTO - Patent Claims Research Dataset: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  3. SSRN - Patent Claims and Patent Scope: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2844964
  4. FDA - Patent Term Extension of U.S. Patent No. 10,125,171 B2: https://downloads.regulations.gov/FDA-2022-E-2199-0002/attachment_1.pdf
  5. Pharsight - GreyB - Empaveli patent expiration: https://pharsight.greyb.com/drug/empaveli-patent-expiration

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,875,893

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Apellis Pharms SYFOVRE pegcetacoplan SOLUTION;INTRAVITREAL 217171-001 Feb 17, 2023 RX Yes Yes 10,875,893 ⤷  Subscribe Y TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF PEGCETACOPLAN ⤷  Subscribe
Apellis Pharms EMPAVELI pegcetacoplan SOLUTION;SUBCUTANEOUS 215014-001 May 14, 2021 RX Yes Yes 10,875,893 ⤷  Subscribe Y TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF PEGCETACOPLAN ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,875,893

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3660033 ⤷  Subscribe 301178 Netherlands ⤷  Subscribe
European Patent Office 3660033 ⤷  Subscribe PA2022010 Lithuania ⤷  Subscribe
European Patent Office 3660033 ⤷  Subscribe 2022C/522 Belgium ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.